Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Revance Therapeutics, Inc. (NASDAQ: RVNC).

Full DD Report for RVNC

You must become a subscriber to view this report.


Recent News from (NASDAQ: RVNC)

Revance to Participate in the UBS Global Healthcare Conference
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in New York, NY. Chief Financial Of...
Source: Business Wire
Date: May, 15 2018 16:05
Will Mullets Bail Out Allergan?
Allergan CEO Brent Saunders. Source: Business Insider I have been bearish on Allergan ( AGN ) since the second half of 2017. I thought the company's Q2 2017 revenue growth in the high single-digits was driven more by acquisitions than via organic sales. After the company reported Q1 2018 r...
Source: SeekingAlpha
Date: May, 14 2018 10:04
Revance Therapeutics' (RVNC) CEO Dan Browne on Q1 2018 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (RVNC) Q1 2018 Earnings Conference Call May 08, 2018 4:30 P.M. ET Executives Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Dan Browne - President and Chief Executive Officer Lauren Silvernail - Chief Financial Offic...
Source: SeekingAlpha
Date: May, 12 2018 03:02
Revance Therapeutics Announces Two Recent Additions to Its Management Team
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its management team with the appointments of Conor Gallagher, Ph.D., as Head of Medical Affairs, Aesthe...
Source: Business Wire
Date: May, 09 2018 16:05
Revance Therapeutics misses by $0.26, misses on revenue
Revance Therapeutics (NASDAQ: RVNC ): Q1 EPS of -$0.97 misses by $0.26 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:37
Revance Releases First Quarter 2018 Results
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the first quarter ended March 31, 2018. Recent Company Highlights and Upcoming Milestones for Daxibotulinumt...
Source: Business Wire
Date: May, 08 2018 16:05
Allergan: Too Much Focus On The Bad
If one paid attention solely to the news flow on Allergan plc ( AGN ), the general assumption would be that the biopharma is struggling to survive. The stock is down some 50% from the all-time high of $330 in mid-2015 due to these overblown fears. Source: Botox website Exclusivity Risk...
Source: SeekingAlpha
Date: May, 02 2018 12:15
Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics - New Research Emphasizes Economic Growt
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Independent Bank Group, Inc (NASDAQ:IBTX), Eclipse Resources Corporation (...
Source: GlobeNewswire
Date: May, 02 2018 07:50
Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn McDowell as Senior Vice President, General ...
Source: Business Wire
Date: May, 01 2018 16:05
Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company’s two pivotal SAKURA Phase 3 trials of Daxibotulinumt...
Source: Business Wire
Date: April, 25 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1830.7030.8531.7030.70201,700
2018-05-1730.4030.8030.8030.05152,771
2018-05-1629.4530.4531.3529.25250,913
2018-05-1530.0029.5030.27529.35295,126
2018-05-1430.9030.2031.0030.10263,422

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1821,36866,22032.2682Cover
2018-05-1710,99632,76733.5582Cover
2018-05-1629,89772,02441.5098Short
2018-05-1533,90593,62636.2132Short
2018-05-1430,07175,72639.7103Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RVNC.


About Revance Therapeutics, Inc. (NASDAQ: RVNC)

Logo for Revance Therapeutics, Inc. (NASDAQ: RVNC)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RVNC)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 11 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 19 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 20 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: March, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 02 2018

       

       


      Daily Technical Chart for (NASDAQ: RVNC)

      Daily Technical Chart for (NASDAQ: RVNC)


      Stay tuned for daily updates and more on (NASDAQ: RVNC)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RVNC)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RVNC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of RVNC and does not buy, sell, or trade any shares of RVNC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/